Sorin Group (MIL:SRN) has released the final consolidated results for fiscal 2009. The financial results reported the company’s consolidated full year revenues of €689 million. It’s EBITDA was reported as €99.4 million, and it’s EBIT was €51.5 million. The company’s net profit for the year was €23.2 million, it’s net debt was €181.6 million.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Sorin ‘s Board of Directors has scheduled a shareholders' meeting for April 27, 2010. Their second call meeting will be held on April 28, 2010. The meeting is address the proposal of nomination of the company’s new Directors. For more information, visit www.sorin.com.
Sorin Group (www.sorin.com) is a global company and a leader in the treatment of cardiovascular diseases. The company develops, manufactures and markets medical technologies and innovative therapies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,500 employees worldwide, the Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
